telmisartan -mediated activation of PPARγ is associated with a reduced risk of macrovascular events in patients with diabetes relative to angiotensin-receptor blockers that do not share this property is unknown.
We sought to compare the risk of acute myocardial infarction, heart failure and stroke in older patients whose diabetes was also managed with either telmisartan or any of candesartan, irbesartan, losartan and valsartan. We speculated that, owing to its pleiotropic effects, telmisartan would be associated with a lower risk of macrovascular events in these patients relative to other angiotensin-receptor blockers.
Methods

Study design
We conducted a population-based retrospective cohort study involving Ontario residents with 
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Data sources
We determined medication exposure using data from the Ontario Drug Benefit database, which contains comprehensive records of prescription drugs dispensed to Ontario residents aged 65 years and older. We excluded the first year of eligibility for prescription drug coverage (age 65 yr) to avoid having incomplete medication records. We obtained data on hospital admissions from the Canadian Institute for Health Information's Discharge Abstract Database, which contains detailed clinical information regarding all hospital admissions in Ontario. The abstraction of patient charts is undertaken by trained health information professionals using standard diagno- 
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Identification of cohort
We defined the index date as the date on which the first prescription for a study drug was dispensed.
To restrict our analysis to patients taking these drugs for the first time, we excluded people who had received a prescription for any angiotensinreceptor blocker in the year preceding the index date. We also excluded patients who received their diagnosis of diabetes after they were given a pre-scription for an angiotensin-receptor blocker, patients who had a myocardial infarction in the 5 years preceding the start of treatment and patients who received an ACE inhibitor in conjunction with an angiotensin-receptor blocker. We considered the use of an angiotensinreceptor blocker to be continuous if a prescription was refilled within 1.5-times the number of days of the preceding prescription's supply.
We included patients who switched between formulations of the same drug, but we censored those who either switched to a different angiotensin-receptor blocker during follow-up or who stopped treatment. We considered treatment to have stopped if a prescription was not refilled within 1.5-times the number of days of the preceding prescription's supply. In addition, we censored patients after 5 years of total observation time, at death or at the end of follow-up (Mar. 31, 2011) , whichever occurred first.
Outcome measures
Our primary outcome was a composite of admission to hospital for acute myocardial infarction, heart failure or stroke. In secondary analyses, we determined the time to each outcome separately, as well as the time to death from any cause. For patients with multiple admissions to hospital during the study period, we considered only the first admission as an outcome. We determined dates of death using the Registered Persons Database and identified diagnoses during hospital admissions using the relevant codes from the 9th and 10th editions of the International Classification of Diseases (Appendix 1, available at www .cmaj .ca /lookup /suppl /doi :10 .1503 /cmaj .121771 / -/DC1).
Statistical analysis
We calculated descriptive statistics for patients' baseline demographic and clinical characteristics and used standardized differences to test for intergroup differences. Standardized differences of less than 0.1 suggest good balance between groups for a given covariable. 19 We conducted time-to-event analyses for the primary outcome using multivariable Cox proportional hazards regression to adjust for baseline demographic and clinical variables (Appendix 2, available at www .cmaj .ca /lookup /suppl /doi :10 .1503 /cmaj .121771 / -/DC1). We used patients taking irbesartan as the reference group. We selected irbesartan as the referent drug a priori because, like telmisartan, it has a long elimination half-life and has shown superior anti hypertensive efficacy relative to comparative angiotensin-receptor blockers. [20] [21] [22] [23] [24] Finally, we conducted a doseresponse assessment in which we considered low, medium and high doses of angiotensin-receptor blockers to be time-dependent covariables, using low-dose treatment as the reference. We verified the proportional hazards assumption by testing the statistical significance of a time-dependent treatment variable and by visually inspecting the estimated log(-log) survival curves. All analyses were performed using SAS version 9.2. This study was approved by the Research Ethics Board of the Sunnybrook Health Sciences Centre, Toronto, Ontario.
Results
We identified 54 186 patients with diabetes who started treatment with an angiotensin-receptor blocker during the study period. Of these patients, 10 940 (20.2%) took candesartan, 12 691 (23.4%) took irbesartan, 8411 (15.5%) took losartan, 8182 (15.1%) took telmisartan and 13 962 (25.8%) took valsartan (Table 1 ). For the primary outcome, patients were collectively followed for a total of 107 315 person-years of treatment. Overall, patients were highly similar with respect to demographic characteristics, the specialties of the prescribing physicians, comorbid illnesses and concomitant medications ( Table 1 ).
In the main analysis, the primary outcome (admission to hospital for either acute myocardial infarction, heart failure or stroke) occurred in 2712 (5.0%) patients taking an angiotensinreceptor blocker. After multivariable adjustment (Appendix 2), we found that telmisartan (adjusted hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.74-0.97) and valsartan (adjusted HR 0.86, 95% CI 0.77-0.96) were associated with a significantly lower risk of the primary outcome when compared with irbesartan ( Figure 1) . In contrast, we found no difference in the risk of the primary outcome between irbesartan and either losartan (adjusted HR 0.93, 95% CI 0.83-1.05) or candesartan (adjusted HR 0.99, 95% CI 0.89-1.11) (Figure 1 ).
In the secondary analyses, we identified 2708 deaths, 1505 admissions to hospital for heart failure, 806 admissions for acute myocardial infarction and 804 admissions for stroke. We found a lower risk of heart failure with telmisartan versus irbesartan (adjusted HR 0.80, 95% CI 0.66-0.96), but we saw no significant differences between angiotensin-receptor blockers in all other comparisons (Figure 2) .
In the dose-response analysis, we found no differences in the risk of the primary outcome with either moderate (adjusted HR 1.04, 95% CI 0.95-1.14) or high (adjusted HR 1.05, 95% CI 0.90-1.23) doses of angiotensin-receptor blockers relative to low doses of these drugs. Our main findings did not change appreciably after adjusting for dose (Appendix 3, available at www .cmaj .ca /lookup /suppl /doi :10 .1503 /cmaj .121771 / -/DC1), although the effectiveness of valsartan was somewhat attenuated (adjusted HR 0.88, 95% CI 0.77-1.0).
Interpretation
In this population-based study of more than 50 000 older adult patients with diabetes starting treatment with an angiotensin-receptor blocker, we found that valsartan and telmisartan were associated with a reduced risk of admission to hospital for either stroke, myocardial infarction or heart failure relative to irbesartan. Furthermore, telmisartan was associated with a lower risk of admission to hospital for heart failure when compared with irbesartan. Our findings suggest that statistically important differences exist in the effectiveness of angiotensin-receptor blockers when used for the prevention of diabetes-related macrovascular disease, and that a class effect for these agents may not be assumed when used for this purpose in clinical practice.
Although angiotensin-receptor blockers share common structural features, important pharmacologic differences exist between the drugs that may explain our results. Specifically, at clinically attainable serum concentrations, telmisartan is unique among these drugs in its ability to structurally interact with and activate the PPARγ receptor, a ligand-activated transcription factor that regulates lipid metabolism and insulin sensitivity. 8, 25 Because telmisartan is a partial agonist of PPARγ, it is not associated with the adverse ef fects typically seen with full agonists (e.g., thia zo lidinediones), such as sodium and water retention, edema and heart failure. 26, 27 Randomized controlled trials and observational studies comparing cardiovascular outcomes and mortality among patients with diabetes taking individual angiotensin-receptor blockers are lacking. A previous observational study comparing 5 angiotensin-receptor blockers in patients with congestive heart failure found no difference in all-cause mortality between people using telmisartan and those using losartan, but the conclusions were limited by a small sample size (only 143 patients received telmisartan). 28 Our study builds upon the results of smaller trials involving patients with diabetes in which telmisartan was associated with significantly greater reductions in serum lipid levels, plasma glucose concentration, glycated hemoglobin levels and markers of insulin resistance relative to other angiotensin-receptor blockers. [9] [10] [11] [12] [13] In addition, we saw a reduced risk of our primary outcome among patients receiving valsartan. Although this effect was attenuated after adjusting for dose, some evidence suggests that valsartan may impart cardioprotective effects in patients with diabetes unrelated to dose or to the drug's efficacy as an antihypertensive agent. Valsartan has inhibited platelet aggregation in a manner that was neither dose-nor timedependent, an effect that was more pronounced among patients with diabetes relative to those without the disease. 29 
Limitations
As with all observational studies, it is possible that our results are biased by intergroup differences in the baseline risk of macrovascular disease and death. However, this seems unlikely, because all groups were highly similar with respect to baseline characteristics, such that any residual differences were negligible and unlikely to account for our results. Furthermore, we adjusted our analyses for an array of important clinical and sociodemographic predictors of angiotensin-receptor blocker use and macrovascular disease.
Although we had no access to clinical information such as smoking history or body mass index, these limitations apply equally to each of the angiotensin-receptor blockers we investigated. Thus, it is difficult to conceive of an unmeasured variable that would be strongly associated with our outcomes but distributed differentially among the various groups to an extent that could sufficiently compromise our findings. A large randomized controlled trial could conclusively show differences in efficacy among individual angiotensin-receptor blockers in patients with diabetes; however, conducting a trial comparing the efficacy of 5 distinct agents would be expensive and time consuming.
Although miscoding is another possible source of bias in observational studies, we used validated codes for identifying stroke, acute myocardial infection and heart failure in our databases, and differential miscoding among patients using angiotensin-receptor blockers is unlikely. [30] [31] [32] Finally, our study involved patients with diabetes aged 66 years and older. Thus, our findings may not be applicable to younger patients or to patients with hypertension who do not have diabetes.
Conclusion
Our results suggest that telmisartan and valsartan are associated with a lower risk of admission to hospital for heart failure, stroke or acute myocardial infarction in older patients with diabetes. Pending confirmatory data from additional observational studies or randomized controlled trials, we suggest that a class effect may not be assumed when using angiotensin-receptor blockers for the prevention of diabetes-related macrovascular complications or heart failure, and that telmisartan and valsartan may be the preferred drugs for this indication.
